Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARIFY MS Extension: 4-year cognition and quality-of-life follow-up after cladribine tablets
NL-OMON49089Phase 4Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS) and relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck & Co. Primary endpoint: No or minimal decline in cognitive function at Month 48 versus baseline. Started Sep 2021; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NL-OMON49089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49089.